Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Favrille cancer product receives fast track status
The B-cell follicular non-Hodgkin’s lymphoma (NHL) treatment is Favrille’s lead product candidate for this disease. The drug is currently in a pivotal phase III clinical trial following Rituxan
The B-cell follicular non-Hodgkin’s lymphoma (NHL) treatment is Favrille’s lead product candidate for this disease. The drug is currently in a pivotal phase III clinical trial following Rituxan
According to Pluristem, the development of this new advanced engineered graft that replenishes the bone marrow of blood cancer patients has the potential to save the lives of
A complete understanding of the protein’s functioning will be a key factor for development of future therapeutic interventions, according to the researchers. The work focuses on apoE4, one
The boards of directors of both companies have unanimously approved the revised J&J offer and the Guidant board of directors is recommending its shareholders vote in favor of
Vitragan is ISTA’s proprietary formulation of highly purified ovine hyaluronidase, which is commonly known in the US as vitrase. A vitreous hemorrhage occurs when retinal blood vessels rupture
The drug is already approved for the prevention of nausea and vomiting caused by highly emetogenic chemotherapy treatments. Both approvals are for Emend in combination with other anti-emetics.
Under the agreement, Safetek is granted exclusive inhibition compounds, world-wide licensing rights for all of Matrix’s intellectual property relating to its thrombin including the full scope of potential
The two companies will perform joint research funded by Centocor applying the unique properties of nanobodies. The companies will work jointly on novel approaches for administration and delivery
Teikoku Seiyaku will be responsible for the further development of Fentanyl Taifun in Japan, building on Lab Pharma’s global development plan for European and North American markets. Under
The merger, first announced in early December 2005, creates a late-stage company with two clinical stage compounds and a robust pipeline of preclinical candidates. In connection with the